Ginkgo Bioworks Holdings, Inc. (DNA): Price and Financial Metrics

Ginkgo Bioworks Holdings, Inc. (DNA): $0.28

0.02 (-7.62%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add DNA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#257 of 354

in industry

DNA Price/Volume Stats

Current price $0.28 52-week high $2.54
Prev. close $0.30 52-week low $0.26
Day low $0.28 Volume 38,328,500
Day high $0.31 Avg. volume 40,703,988
50-day MA $0.51 Dividend yield N/A
200-day MA $1.13 Market Cap 619.16M

DNA Stock Price Chart Interactive Chart >


Ginkgo Bioworks Holdings, Inc. (DNA) Company Bio


Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.


DNA Latest News Stream


Event/Time News Detail
Loading, please wait...

DNA Latest Social Stream


Loading social stream, please wait...

View Full DNA Social Stream

Latest DNA News From Around the Web

Below are the latest news stories about GINKGO BIOWORKS HOLDINGS INC that investors may wish to consider to help them evaluate DNA as an investment opportunity.

OneOne Biosciences Partners with Ginkgo Bioworks to Advance its Platform and Nitrogen Fixation Microbial Product

OneOne Biosciences, a French startup building a comprehensive suite of agricultural microbial solutions for farmers, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. This collaboration will leverage Ginkgo's robust ag biologicals infrastructure, biotechnological expertise, and Strain Optimization Services to accelerate OneOne's research and product development in agricultural microbial solutions.

Yahoo | December 20, 2023

GreenLab Selects Ginkgo Enzyme Services to Develop Novel Enzyme That Breaks Down 'Forever Chemicals'

GreenLab, an emerging next generation plant-biotechnology company producing complex proteins in corn, today announced a new partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. GreenLab is developing a product with the purpose of degrading PFAS and will leverage Ginkgo Enzyme Services to discover a novel enzyme of critical importance for use in this application.

Yahoo | December 19, 2023

U.S. Department of Energy Awards Team Led by Ginkgo Bioworks Funding to Develop Algal Crop Protection Solutions

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that a Ginkgo-led team — including partners from the Pacific Northwest National Laboratory, Colorado School of Mines, and Global Algae Innovations — has been awarded funding through the U.S. Department of Energy's (DOE) Bioenergy Technologies Office (BETO). The scope of the project will be to develop a new approach to algal crop protection, inspired by integrated pest managem

Yahoo | December 19, 2023

FGen AG, a Ginkgo Bioworks Subsidiary, Awarded Funding Through European Innovation Council's Pathfinder Programme For Sustainable Milk Protein Production Project

FGen AG, a subsidiary of Ginkgo Bioworks (NYSE: DNA), based in Switzerland, has been awarded funding through the European Innovation Council's (EIC) Pathfinder Challenge program. This is part of an international research consortium that aims to develop a new, sustainable approach to milk protein production using only carbon dioxide and electricity. The consortium, led by Finnish food tech innovator, Solar Foods, and also including leading researchers from the University of Groningen and RWTH Aac

Yahoo | December 19, 2023

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

John Blankenhorn on InvestorPlace | December 16, 2023

Read More 'DNA' Stories Here

DNA Price Returns

1-mo -34.02%
3-mo -66.78%
6-mo -77.95%
1-year -88.24%
3-year -97.18%
5-year N/A
YTD -83.43%
2023 0.00%
2022 -79.66%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!